Profile data is unavailable for this security.
About the company
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations. The Company is mainly engaged in three businesses. The contract development and manufacturing organization (CDMO) business mainly provides pharmaceutical companies with CDMO services for the entire preparation industry chain. The specialty API business is mainly engaged in the production and sales of APIs. The preparation business is mainly engaged in the production and sales of preparations. The Company's main products include valsartan, losartan, perindopril, rosuvastatin calcium, atorvastatin calcium and pregabalin. The Company's products are mainly used in cardiovascular, central nervous, antiviral, hypoglycemic, gastrointestinal and other therapeutic areas. The Company mainly conducts its businesses in domestic and overseas markets.
- Revenue in CNY (TTM)1.24bn
- Net income in CNY-326.25k
- Incorporated2004
- Employees2.35k
- LocationNingbo Menovo Pharmaceutical Co LtdRoom 1406NINGBO 315048ChinaCHN
- Phone+86 57 487916065
- Fax+86 57 487918601
- Websitehttp://www.menovopharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jiangsu Lianhuan Pharmaceutical Co. Ltd | 2.35bn | 136.37m | 2.55bn | 1.30k | 18.67 | 1.85 | -- | 1.09 | 0.4777 | 0.4777 | 8.22 | 4.81 | 0.8255 | 3.44 | 4.60 | 1,810,024.00 | 5.50 | 5.93 | 11.40 | 11.25 | 48.56 | 53.26 | 6.66 | 7.82 | 0.7093 | 6.96 | 0.3522 | 30.64 | 11.20 | 16.36 | -4.50 | 12.91 | 9.35 | 13.97 |
Ningbo Menovo Pharmaceutical Co Ltd | 1.24bn | -326.25k | 2.68bn | 2.35k | 8,619.72 | 1.27 | -- | 2.16 | -0.0323 | -0.0323 | 5.32 | 9.67 | 0.2802 | 1.29 | 5.28 | 527,886.10 | 0.0661 | 4.94 | 0.0989 | 7.83 | 29.16 | 35.39 | 0.2359 | 13.71 | 0.78 | 1.89 | 0.4176 | 10.78 | -16.51 | 7.46 | -96.58 | -34.53 | -6.03 | -32.54 |
Zhejiang Shapuaisi Pharmaceutical Co Ltd | 540.27m | -72.66m | 2.79bn | 1.39k | -- | 1.65 | -- | 5.16 | -0.1922 | -0.1922 | 1.44 | 4.46 | 0.2581 | 2.94 | 13.86 | 390,086.00 | -3.48 | -0.7573 | -4.00 | -0.8713 | 51.90 | 58.02 | -13.49 | -2.45 | 0.8094 | -- | 0.1284 | -- | 17.37 | 1.21 | -43.23 | -- | 30.36 | -- |
GuiZhou YiBai Pharmaceutical Co., Ltd. | 2.51bn | -131.00m | 2.81bn | 5.51k | -- | 1.03 | -- | 1.12 | -0.1654 | -0.1654 | 3.17 | 3.44 | 0.5335 | 1.48 | 10.54 | 455,445.80 | -3.01 | 0.8648 | -4.09 | 1.18 | 63.72 | 74.87 | -5.63 | 1.45 | 1.26 | -3.93 | 0.2515 | 216.36 | 3.12 | -6.19 | 124.25 | -- | -16.51 | -- |
Henan Taloph Pharmaceutical Stock Co Ltd | 2.00bn | 108.51m | 2.82bn | 2.35k | 26.44 | 1.80 | -- | 1.41 | 0.1857 | 0.1857 | 3.47 | 2.73 | 0.572 | 3.01 | 2.11 | 851,358.90 | 3.25 | 0.272 | 7.08 | 0.4981 | 28.52 | 27.97 | 5.68 | 0.5501 | 0.81 | 2.99 | 0.4312 | 28.70 | 5.57 | 11.62 | 160.32 | -- | -8.27 | -- |
Holder | Shares | % Held |
---|---|---|
Rongtong Fund Management Co., Ltd.as of 31 Dec 2023 | 3.67m | 1.74% |
Chang Xin Asset Management Co., Ltd.as of 31 Dec 2023 | 3.66m | 1.73% |
China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 2.95m | 1.40% |
China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 1.32m | 0.63% |
ABC-CA Fund Management Co., Ltd.as of 31 Dec 2023 | 857.22k | 0.41% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 770.09k | 0.37% |
Huatai-PineBridge Fund Management Co., Ltd.as of 31 Dec 2023 | 624.98k | 0.30% |
Great Wall Fund Management Co., Ltd.as of 31 Dec 2023 | 620.00k | 0.29% |
UBS SDIC Fund Management Co., Ltd.as of 31 Dec 2023 | 612.40k | 0.29% |
Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 520.60k | 0.25% |